Updates are available Correction dated 2025-02-11
Click to view Correction: https://doi.org/10.1186/s12883-025-04055-1
-
Authors
Nerdal, Vilde
Gjestad, Elise
Saltvedt, Ingvild
Munthe-Kaas, Ragnhild
Ihle-Hansen, Hege
Ryum, Truls
Lydersen, Stian
Grambaite, Ramune
-
Funding
Funding for this research was provided by:
NTNU Norwegian University of Science and Technology
- License Information
-
More Information
Article History
Received: 15 January 2022
Accepted: 14 June 2022
First Online: 27 June 2022
Change Date: 25 August 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Change Date: 11 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12883-025-04055-1
Declarations
:
: Both the Nor-COAST study as a whole and this particular project was approved by Regional Committees for Medical and Health Research (REC), which is the ethics board responsible for all medical research in Norway. The REC number for the Nor-COAST study is 2015/171, and the REC number for the current study is 2019/854. The Nor-COAST study was registered in ClinicalTrials.gov (NCT02650531). The research is performed according to the Helsinki declaration. Participation is based on written informed consent. If the participants were unable to provide informed consent due to medical condition or severe dementia, participation was based on informed consent given by family proxies.
: Not applicable.
: IS has been an investigator in the drug trial Boehringer-Ingelheim 1346.0023. HH is associate editor in BMC Neurology. None of the other authors have any conflicts of interests to declare.
